Literature DB >> 28099863

Satb1: Restraining PD1 and T Cell Exhaustion.

Briana G Nixon1, Ming O Li2.   

Abstract

Mechanisms that govern PD1 expression and exhaustion in T cells are not fully understood. In this issue of Immunity, Stephen et al. (2017) uncover a key role for the genome organizer Satb1 in restraining PD1 expression and promoting tumor immunity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28099863     DOI： 10.1016/j.immuni.2017.01.002

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  8 in total

Review 1.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

2.  MicroRNA-409 regulates the proliferation and invasion of breast cancer cell lines by targeting special AT-rich sequence-binding protein 1 (SATB1).

Authors:  Zhi Chen; Mei-Xiang Sang; Cui-Zhi Geng; Hui-Qun Jia
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Chronic Exposure to Malaria Is Associated with Inhibitory and Activation Markers on Atypical Memory B Cells and Marginal Zone-Like B Cells.

Authors:  Itziar Ubillos; Joseph J Campo; Pilar Requena; Maria Ome-Kaius; Sarah Hanieh; Honor Rose; Paula Samol; Diana Barrios; Alfons Jiménez; Azucena Bardají; Ivo Mueller; Clara Menéndez; Stephen Rogerson; Gemma Moncunill; Carlota Dobaño
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

4.  Expression and clinical significance of SATB1 and TLR4 in breast cancer.

Authors:  Xuebo Wang; Xiumei Yu; Qingli Wang; Yingying Lu; Haixia Chen
Journal:  Oncol Lett       Date:  2017-07-12       Impact factor: 2.967

5.  Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.

Authors:  Dovile Zilenaite; Allan Rasmusson; Renaldas Augulis; Justinas Besusparis; Aida Laurinaviciene; Benoit Plancoulaine; Valerijus Ostapenko; Arvydas Laurinavicius
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

6.  Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models.

Authors:  Jordi Guiteras; Laura De Ramon; Elena Crespo; Nuria Bolaños; Silvia Barcelo-Batllori; Laura Martinez-Valenzuela; Pere Fontova; Marta Jarque; Alba Torija; Oriol Bestard; David Resina; Josep M Grinyó; Joan Torras
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

7.  A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting.

Authors:  Yanmei He; Lei Lei; Jun Cao; Xiaotong Yang; Shengsheng Cai; Fan Tong; Dennis Huang; Heng Mei; Kui Luo; Huile Gao; Bin He; Nicholas A Peppas
Journal:  Sci Adv       Date:  2021-02-05       Impact factor: 14.136

8.  T-Cell Exhaustion Status Under High and Low Levels of Hypoxia-Inducible Factor 1α Expression in Glioma.

Authors:  Shuai Liu; Xing Liu; Chuanbao Zhang; Wei Shan; Xiaoguang Qiu
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.